# Comparability DE vs CD-CHO1

> **NCT00277199** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 30 (—)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT00277199
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2011-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277199, "Comparability DE vs CD-CHO1". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00277199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*